A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2016
At a glance
- Drugs Epratuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms EMBODY4
- Sponsors UCB; UCB Pharma Inc
- 14 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Aug 2013 Planned End Date changed from 1 Feb 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.
- 21 Mar 2012 Additional trial locations added as reported by Australian New Zealand Clinical Trials Registry record.